X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (8095) 8095
Book Review (1200) 1200
Publication (614) 614
Book Chapter (22) 22
Magazine Article (19) 19
Conference Proceeding (8) 8
Dissertation (7) 7
Book / eBook (3) 3
Web Resource (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (7257) 7257
humans (6246) 6246
male (3910) 3910
female (3564) 3564
indoles - therapeutic use (3369) 3369
indoles - adverse effects (3156) 3156
middle aged (2750) 2750
aged (2134) 2134
animals (2116) 2116
adult (2102) 2102
indoles - pharmacology (1817) 1817
indoles - administration & dosage (1740) 1740
oncology (1563) 1563
pharmacology & pharmacy (1410) 1410
treatment outcome (1320) 1320
cancer (1049) 1049
antineoplastic agents - adverse effects (967) 967
pyrroles - adverse effects (938) 938
pyrroles - therapeutic use (882) 882
antineoplastic agents - therapeutic use (862) 862
sunitinib (831) 831
dose-response relationship, drug (811) 811
mice (756) 756
rats (736) 736
double-blind method (732) 732
carcinoma, renal cell - drug therapy (721) 721
care and treatment (720) 720
abridged index medicus (690) 690
kidney neoplasms - drug therapy (683) 683
analysis (675) 675
aged, 80 and over (659) 659
indoles - pharmacokinetics (601) 601
drug therapy (570) 570
pyrroles - administration & dosage (506) 506
efficacy (501) 501
therapy (500) 500
research (491) 491
time factors (489) 489
sulfonamides - adverse effects (462) 462
medicine & public health (461) 461
drug therapy, combination (423) 423
adolescent (419) 419
neurosciences (419) 419
double-blind (414) 414
metastasis (414) 414
indole (409) 409
indoles - chemistry (408) 408
tyrosine kinase inhibitor (406) 406
kidney neoplasms - pathology (400) 400
niacinamide - analogs & derivatives (387) 387
drug administration schedule (386) 386
article (385) 385
safety (381) 381
chemotherapy (379) 379
antineoplastic agents (375) 375
endothelial growth-factor (373) 373
risk factors (373) 373
expression (372) 372
clinical trials as topic (371) 371
antineoplastic agents - administration & dosage (370) 370
disease-free survival (364) 364
administration, oral (358) 358
clinical trials (358) 358
sulfonamides - therapeutic use (358) 358
antimitotic agents (355) 355
clinical neurology (351) 351
melanoma - drug therapy (350) 350
tumors (350) 350
medicine, general & internal (346) 346
indoles (336) 336
survival (336) 336
health aspects (332) 332
antineoplastic combined chemotherapy protocols - therapeutic use (330) 330
retrospective studies (328) 328
protein kinase inhibitors - adverse effects (327) 327
neoplasms - drug therapy (326) 326
apoptosis (322) 322
urology & nephrology (319) 319
pharmacokinetics (318) 318
melanoma (317) 317
sorafenib (317) 317
young adult (315) 315
biochemistry & molecular biology (313) 313
cell line, tumor (313) 313
prospective studies (313) 313
disease models, animal (307) 307
bevacizumab (304) 304
protein kinase inhibitors - therapeutic use (298) 298
interferon-alpha (297) 297
rats, sprague-dawley (289) 289
toxicity (286) 286
toxicology (283) 283
angiogenesis (282) 282
trial (282) 282
hypertension (278) 278
angiogenesis inhibitors - therapeutic use (273) 273
renal-cell carcinoma (273) 273
antineoplastic agents - pharmacology (272) 272
mutation (270) 270
angiogenesis inhibitors - adverse effects (268) 268
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (7704) 7704
German (104) 104
French (79) 79
Japanese (59) 59
Russian (47) 47
Spanish (33) 33
Chinese (25) 25
Dutch (15) 15
Danish (14) 14
Italian (14) 14
Hungarian (9) 9
Czech (8) 8
Swedish (5) 5
Norwegian (4) 4
Polish (4) 4
Portuguese (3) 3
Romanian (2) 2
Finnish (1) 1
Hebrew (1) 1
Korean (1) 1
Lithuanian (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


British Journal of Dermatology, ISSN 0007-0963, 11/2009, Volume 161, Issue 5, pp. 1045 - 1051
Summary Background  The multitargeted kinase inhibitors sorafenib and sunitinib have improved treatment of solid tumours including renal cell carcinoma and... 
sunitinib | sorafenib | cutaneous adverse effects | Cutaneous adverse effects | Sunitinib | Sorafenib | THERAPY | HAIR | MANAGEMENT | KIT | IMATINIB | HAND-FOOT | FOOT SKIN REACTION | DERMATOLOGY | Niacinamide - analogs & derivatives | Humans | Middle Aged | Hand Dermatoses - chemically induced | Male | Phenylurea Compounds | Antineoplastic Agents - administration & dosage | Benzenesulfonates - administration & dosage | Protein Kinase Inhibitors - adverse effects | Skin Diseases - pathology | Indoles - administration & dosage | Benzenesulfonates - adverse effects | Young Adult | Pyridines - adverse effects | Carcinoma, Hepatocellular - drug therapy | Antineoplastic Agents - adverse effects | Pyrroles - administration & dosage | Aged, 80 and over | Pyrroles - adverse effects | Adult | Female | Retrospective Studies | Carcinoma, Renal Cell - drug therapy | Drug Eruptions - etiology | Skin Diseases - chemically induced | Pyridines - administration & dosage | Administration, Oral | Protein Kinase Inhibitors - administration & dosage | Indoles - adverse effects | Gastrointestinal Stromal Tumors - drug therapy | Stomatitis - chemically induced | Foot Dermatoses - chemically induced | Alopecia - chemically induced | Aged | Kidney Neoplasms - drug therapy | Antimitotic agents | Complications and side effects | Liver cancer | Medical colleges | Care and treatment | Antineoplastic agents | Tumors | Index Medicus
Journal Article
Journal Article
Neurobiology of Disease, ISSN 0969-9961, 2008, Volume 33, Issue 2, pp. 193 - 206
Abstract The dysregulation of glycogen synthase kinase-3 (GSK3) has been implicated in Alzheimer disease (AD) pathogenesis and in Aβ-induced neurotoxicity,... 
Neurology | Tau | Neuron damage | c- jun N-terminal kinase | GSK3 | Beta-amyloid | Alzheimer's | c-jun N-terminal kinase | NEUROFIBRILLARY TANGLES | TYROSINE PHOSPHORYLATION | GLYCOGEN-SYNTHASE KINASE-3 | AMYLOID PLAQUES | NEUROSCIENCES | NEUROPSYCHIATRIC SYMPTOMS | IN-VIVO | PRECURSOR PROTEIN | REDUCES TAU PHOSPHORYLATION | TRANSGENIC MICE | COGNITIVE DEFICITS | Phosphorylation | Amyloid beta-Peptides - pharmacology | Caspase 3 - metabolism | Gliosis - chemically induced | Maleimides - adverse effects | tau Proteins - metabolism | JNK Mitogen-Activated Protein Kinases - metabolism | Hippocampus - drug effects | Glycogen - metabolism | Maleimides - therapeutic use | DNA Fragmentation | Neurons - metabolism | Alzheimer Disease - chemically induced | Neurons - drug effects | Disease Models, Animal | Enzyme Inhibitors - adverse effects | Glycogen Synthase Kinase 3 - antagonists & inhibitors | Alzheimer Disease - therapy | Cells, Cultured | Rats | Glycogen Synthase Kinase 3 - metabolism | Enzyme Inhibitors - therapeutic use | Rats, Sprague-Dawley | Animals | Indoles - adverse effects | Maze Learning | Indoles - therapeutic use | Hippocampus - physiology | Nerve Degeneration - drug therapy | Proteolipids | Enzymes | Lipoproteins | Synthesis | Glycogen | Neurons | Analysis | Depression, Mental | GABA | Blood lipoproteins | Saturated fatty acids | Alzheimer's disease | Index Medicus
Journal Article
Journal of the European Academy of Dermatology and Venereology, ISSN 0926-9959, 01/2015, Volume 29, Issue 1, pp. 61 - 68
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 09/2014, Volume 371, Issue 13, pp. 1265 - 1267
Vemurafenib, a BRAF inhibitor, has been associated with a number of cutaneous adverse effects, mainly through the activation of MAP kinases. Pyogenic granuloma... 
MEDICINE, GENERAL & INTERNAL | BRAF | MELANOMA | INHIBITION | Drug Eruptions - etiology | Indoles - adverse effects | Skin Neoplasms - drug therapy | Granuloma, Pyogenic - chemically induced | Nose - pathology | Humans | Melanoma - drug therapy | Sulfonamides - adverse effects | Male | Aged | Granuloma, Pyogenic - pathology | Granuloma | Side effects | Metastasis | Mutation | Melanoma
Journal Article
Journal of Psychoactive Drugs, ISSN 0279-1072, 05/2017, Volume 49, Issue 3, pp. 262 - 265
Synthetic cannabinoid receptor agonists are a heterogeneous group of psychotropic drugs functionally related to Δ9-tetrahydrocannabinol. These substances,... 
JWH-122 | Cannabinoids | hallucinations | naphthoylindole | SUBSTANCE ABUSE | PSYCHOLOGY, CLINICAL | Illusions - drug effects | Naphthalenes - adverse effects | Indoles - adverse effects | Follow-Up Studies | Humans | Adolescent | Hallucinations - chemically induced | Male | Cannabinoids - adverse effects | Marijuana | Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2015, Volume 372, Issue 1, pp. 30 - 39
In patients with melanomas containing activating BRAF mutations, the combination of a BRAF inhibitor and a MEK inhibitor improved overall survival, as compared... 
CRITERIA | BRAF-MUTATED MELANOMA | METASTATIC MELANOMA | RAF INHIBITION | MEDICINE, GENERAL & INTERNAL | MEK INHIBITION | ACQUIRED-RESISTANCE | V600E MUTATION | TUMORS | OVERCOME | VEMURAFENIB | Skin Neoplasms - drug therapy | Oximes - adverse effects | Humans | Middle Aged | Oximes - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Imidazoles - administration & dosage | Male | Protein Kinase Inhibitors - adverse effects | Young Adult | Pyridones - administration & dosage | Aged, 80 and over | Adult | Female | Skin Neoplasms - pathology | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Kaplan-Meier Estimate | Mitogen-Activated Protein Kinase Kinases - antagonists & inhibitors | Melanoma - secondary | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Protein Kinase Inhibitors - administration & dosage | Indoles - adverse effects | Sulfonamides - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Adolescent | Intention to Treat Analysis | Survival Analysis | Sulfonamides - adverse effects | Indoles - therapeutic use | Aged | Pyrimidinones - administration & dosage | Mutation | Pyridones - adverse effects | Melanoma - mortality | Patients | Health aspects | Risk factors | Melanoma | Toxicity | Medical treatment | MEK inhibitors | Antitumor activity | Metastasis | Kinases | Cancer therapies | Clinical outcomes | Metastases | Index Medicus | Abridged Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2018, Volume 378, Issue 14, pp. 1277 - 1290
Journal Article